Mike Thompson, MD, PhD, FASCO (@mtmdphd) ranks #13 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 14 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: inMMyCAR, MajesTEC-3, CARTITUDE-4. CMS Open Payments lists no 2025 general payments.
At a Glance
- 14 posts naming a trial since ASH 2025
- 8 trials discussed by name
- Multiple Myeloma: US #13, Global #16 · 14 physicians engaged
- CMS Open Payments lists no 2025 general payments.
This Month
What Mike Thompson, MD, PhD, FASCO has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Mike Thompson, MD, PhD, FASCO
Physicians who reposted Mike Thompson, MD, PhD, FASCO’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #13 | #16 | 57/100 | 14 | 17 | Full ranking |
Trials Mike Thompson, MD, PhD, FASCO Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| inMMyCAR | 4 | #4 of 6 | Dec 9, 2025 |
| MajesTEC-3 | 3 | #5 of 15 | Dec 9, 2025 |
| CARTITUDE-4 | 2 | #7 of 9 | Nov 29, 2025 |
| RASolute 302 | 1 | #56 of 73 | May 26, 2026 |
| HARMONi-6 | 1 | #58 of 74 | May 26, 2026 |
| DETERMINATION | 1 | — | Dec 10, 2025 |
| PROMISE | 1 | — | Dec 6, 2025 |
| IMMUNOPLANT | 1 | — | Nov 29, 2025 |
Mike Thompson, MD, PhD, FASCO on inMMyCAR
MRD-negative outcomes following a novel, in vivo gene therapy generating #CARTcell in Pts w/ RRMM: Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 [Tue, Dec 9, 7:30a] @PhoebeJoyHo1 #ASH25 LBA-1 https://t.co/Cly1aLrFWZ #mmsm #caxtx #mmMRD AE https://t.co/ANXyIUF1zc
MRD-negative outcomes following a novel, in vivo gene therapy generating #CARTcell in Pts w/ RRMM: Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 [Tue, Dec 9, 7:30a] @PhoebeJoyHo1 #ASH25 LBA-1 https://t.co/Cly1aLrFWZ #mmsm #caxtx #mmMRD
MRD-negative outcomes following a novel, in vivo gene therapy generating #CARTcell in Pts w/ RRMM: Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 [Tue, Dec 9, 7:30a] @PhoebeJoyHo1 #ASH25 LBA-1 https://t.co/Cly1aLrFWZ #mmsm #caxtx #mmMRD https://t.co/mj1ZUkm5Tm
Mike Thompson, MD, PhD, FASCO on MajesTEC-3
Ph3 RCT teclistamab + daratumumab vs investigator’s choice of dara-dex + either pomalidomide or bortezomib (DPd/DVd) in Pts w/RRMM: Results of MajesTEC-3 [Dec 9, 2025] @mvmateos et al. @End_myeloma #ASH25 LBA6 https://t.co/05T5SpqCpg #NCT05083169 #mmsm #IDonc PFS https://t.co/xPCzZ94ewH
Ph3 RCT teclistamab + daratumumab vs investigator’s choice of dara-dex + either pomalidomide or bortezomib (DPd/DVd) in Pts w/RRMM: Results of MajesTEC-3 [Tue, Dec 9, 7:30-9:00a] @mvmateos et al. @End_myeloma #ASH25 LBA6 https://t.co/05T5SpqCpg #NCT05083169 #mmsm #IDonc
Ph3 RCT teclistamab + daratumumab vs investigator’s choice of dara-dex + either pomalidomide or bortezomib (DPd/DVd) in Pts w/RRMM: Results of MajesTEC-3 [Tue, Dec 9, 7:30-9:00a] Mateos et al. @End_myeloma #ASH25 LBA6 https://t.co/05T5SpqCpg #NCT05083169 #mmsm #IDonc https://t.co/eDzVNQnlIj
Mike Thompson, MD, PhD, FASCO on CARTITUDE-4
Earlier cilta-cel assoc w/ better immune fitness & stronger immune effects - correlative analysis of PB & BM tumor microenvironment (TME) from CARTITUDE-4 study [Nov 3, 2025] Parekh et al. #ASH25 abs25-8211 PID 92 https://t.co/pJwTOWV5BL #mmsm #CARTcell #ImmunoOnc #IDonc https://t.co/JcNuJHJ9lg
Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of Pts w/ relapsed, len-refractory MM [Nov 3, 2025] @bhemato et al. #ASH25 abs25-8216 PID 2215 https://t.co/u6hame6Rm9 #mmsm #CARTcell #IDonc n=196 https://t.co/iCnEZTKtKL
Mike Thompson, MD, PhD, FASCO on RASolute 302
#ASCO26 LBA5 - Wolpin - Daraxonrasib RAS(ON) multi-selective inhibitor vs chemo in prior Tx metastatic pancreatic adenocarcinoma (mPDAC) - Ph3 RASolute 302 [May 31, 2026] https://t.co/oWEeVo2oyq #NCT06625320 #pancsm #caxtx #PrecisionMedicine
Mike Thompson, MD, PhD, FASCO on HARMONi-6
#ASCO26 LBA4 - Zhiwei - Ivonescimab + chemo vs tislelizumab + chemo 1L sq NSCLC - Ph3 HARMONi-6 [May 31, 2026] Zhiwei et al. https://t.co/oWEeVo2oyq #NCT05840016 #lcsm #ImmunoOnc
Mike Thompson, MD, PhD, FASCO on DETERMINATION
Impact of Duffy genotype on PFS w/ RVd +/- ASCT & continuous R maintenance in Pts w/ NDMM: Updated subgroup analysis of the phase 3 DETERMINATION trial [Nov 3, 2025] @LaurenMerzMD et al. #ASH25 abs25-4186 PID 1033 https://t.co/sIQK3u3pha #mmsm #bmtsm #CancerDisparities #globonc https://t.co/7LMhc5jko5
Mike Thompson, MD, PhD, FASCO on PROMISE
Results of the PROMISE study from ~30,000 individuals screened for monoclonal gammopathies [Nov 3, 2025] @SabineWaelAllam et al. @IrenemGhobrial #ASH25 abs25-10090 https://t.co/3mGdW3yKUD #NCT03689595 #mmsm https://t.co/uzbvwF4h92
Mike Thompson, MD, PhD, FASCO on IMMUNOPLANT
Ph 2 abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses s/p NDMM combo Tx for #mmMRD positivity (IMMUNOPLANT Study) [Nov 3, 2025] Kazandijian et al. @DrOlaLandgren #ASH25 abs25-8386 PID 248 https://t.co/Mss2dJr9mM #mmsm https://t.co/32YisRDVlo
Mike Thompson, MD, PhD, FASCO’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
MonumenTAL BsA in MM - @PlasmaCellPete #EHA2026 #mmsm weight loss https://t.co/Q2MsYVUw7z
Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO https://t.co/776r7qmxcY #ASCO26 #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm #scmsm https://t.co/UH87rER3Xu
Whole genome sequencing [WGS] to identify novel, clinically relevant findings missed by standard of care for Pts w/ myelodysplastic syndrome [MDS] - @AlexBataller et al @garciamanero @UTMDAnderson @TempusAI #ASCO26 abst 6570 Pst 363 https://t.co/t7aNW89eRL #MDSsm #leusm #cagenome
EVERY CANCER. EVERY PATIENT. EVERYWHERE. @ConquerCancerFd of the American Society of Clinical Oncology (@ASCO) raises funds to support the world's leading researchers who are improving treatments & discovering cures for patients around the world. https://t.co/du6r6gdsgV #ASCO26
#ASCO26 LBA2 - Dickson -SARC041: Ph3 DBRCT abemaciclib vs placebo in Pts w/ adv dedifferentiated liposarcoma [May 31, 2026] https://t.co/oWEeVo2oyq #NCT04967521 #scmsm
Industry Payments
CMS Open Payments · 2025 general payments
$0 across 0 payments